

Prescriber Criteria Form

Balversa 2024 PA Fax 2966-A v1 010124.docx  
Balversa (erdafitinib)  
Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.  
Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**.  
Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process.  
When conditions are met, we will authorize the coverage of Balversa (erdafitinib).

Drug Name:  
Balversa (erdafitinib)

<b>Patient Name:</b>		
<b>Patient ID:</b>		
<b>Patient DOB:</b>	<b>Patient Phone:</b>	
<b>Prescriber Name:</b>		
<b>Prescriber Address:</b>		
<b>City:</b>	<b>State:</b>	<b>Zip:</b>
<b>Prescriber Phone:</b>	<b>Prescriber Fax:</b>	
<b>Diagnosis:</b>	<b>ICD Code(s):</b>	

<b>Please circle the appropriate answer for each question.</b>			
1	Does the patient have a diagnosis of locally advanced or metastatic urothelial carcinoma? [If yes, then skip to question 6.]	Yes	No
2	Does the patient have a diagnosis of recurrent primary carcinoma of the urethra? [If yes, then skip to question 6.]	Yes	No
3	Does the patient have a diagnosis of urothelial carcinoma of the bladder with muscle invasive local recurrence or persistent disease in a preserved bladder? [If yes, then skip to question 6.]	Yes	No
4	Does the patient have a diagnosis of urothelial carcinoma of the bladder with metastatic or local recurrence post-cystectomy? [If yes, then skip to question 6.]	Yes	No
5	Does the patient have a diagnosis of Stage II-IV urothelial carcinoma of the bladder? [If no, then no further questions.]	Yes	No
6	Does the disease have a susceptible fibroblast growth factor receptor 3 (FGFR3) or fibroblast growth factor receptor 2 (FGFR2) genetic alteration? [If no, then no further questions.]	Yes	No
7	Is the requested drug being used as subsequent therapy?	Yes	No

Comments:	
-----------	--

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

<b>Prescriber (or Authorized) Signature:</b> _____	<b>Date:</b> _____
--	--------------------